IVERIC bio (ISEE) Stock Jumps 46%: Stifel Launches ISEE At Buy

Starting from September 2, IVERIC bio (ISEE) stock price has been deteriorating. Today’s price is $ 2.2 lower than last Thursday. The stock traded at $ 10.92 that day. The next day, the price dropped to $ 9.39, eventually losing 14%. For one day, Thursday, the cost went up 4%. On September 8, it dipped again, but this time even lower to $ 8.73. At its lowest price in 5 days, the stock traded on September 9 at $ 8.40. Now it’s trading at $8.69. IVERIC bio is a biopharmaceutical company engaged in the discovery and development of new treatment options for retinal diseases with significant unmet medical needs.
IVERIC bio (ISEE) Stock Jumps 46%: Stifel Launches ISEE At BuyStifel analyst Annabel Samimi announced that they start coverage of IVERIC bio (ISEE) with a rating of “buy” and a 12-month target price of $ 22. Iveric may well be the leading treatment for this indication. Zimura has the only known successful study with high statistical significance in the rapidly progressive stage of the disease. Zimura will form the foundation for ISEE’s ownership of GA and the broader dry age-related macular degeneration (AMD) landscape. Gene therapy platform ISEE further strengthens the company’s position in the field of inherited retinal diseases.